Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Giuseppe Giordano

Researcher

Default user image.

RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes

Author

  • Rachel Adams
  • Nicole Daly
  • Elizabeth Robertson
  • Giuseppe N. Giordano

Summary, in English

Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.

Department/s

  • Genetic and Molecular Epidemiology
  • EpiHealth: Epidemiology for Health
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year

2021

Language

English

Publication/Series

Endocrinology, Diabetes and Metabolism

Volume

4

Issue

2

Document type

Journal article

Publisher

John Wiley and Sons

Topic

  • Endocrinology and Diabetes

Keywords

  • biomarkers
  • disease progression
  • novel clinical trial design
  • prediabetes
  • type 2 diabetes mellitus

Status

Published

Research group

  • Genetic and Molecular Epidemiology

ISBN/ISSN/Other

  • ISSN: 2398-9238